-DOCSTART-	
	
BACKGROUND	O
:	O
	
Common	B-Process
etiology	I-Process
of	O
vascular	B-Process
diseases	I-Process
and	O
later	B-Process
-	I-Process
life	I-Process
depression	I-Process
may	O
provide	O
important	B-Data
synergies	I-Data
for	O
prevention	B-Process
.	O
	
We	O
examined	O
whether	O
standard	B-Data
clinical	I-Data
risk	I-Data
profiles	I-Data
developed	O
for	O
vascular	B-Process
diseases	I-Process
also	O
predict	B-Process
depressive	B-Data
symptoms	I-Data
in	O
older	B-Material
adults	I-Material
.	O
	
METHODS	O
:	O
	
Data	O
were	O
drawn	O
from	O
the	B-Method
Whitehall	I-Method
II	I-Method
study	I-Method
with	O
baseline	B-Process
examination	I-Process
in	O
1991	B-Data
;	O
follow	B-Process
-	I-Process
up	I-Process
screenings	I-Process
in	O
1997	B-Data
,	I-Data
2003	I-Data
,	I-Data
and	I-Data
2008	I-Data
;	O
and	O
additional	B-Process
disease	I-Process
ascertainment	I-Process
from	O
hospital	B-Material
data	I-Material
and	O
registry	B-Material
linkage	I-Material
on	O
5318	B-Material
participants	I-Material
(	O
mean	B-Data
age	I-Data
54.8	I-Data
years	I-Data
,	I-Data
31	I-Data
%	I-Data
women	I-Data
)	O
without	O
depressive	B-Data
symptoms	I-Data
at	O
baseline	B-Data
.	O
	
Vascular	B-Data
risk	I-Data
was	O
assessed	B-Process
with	O
the	B-Data
Framingham	I-Data
Cardiovascular	I-Data
,	I-Data
Coronary	I-Data
Heart	I-Data
Disease	I-Data
,	I-Data
and	I-Data
Stroke	I-Data
Risk	I-Data
Scores	I-Data
.	O
	
New	B-Data
depressive	I-Data
symptoms	I-Data
at	O
each	B-Process
follow	I-Process
-	I-Process
up	I-Process
screening	I-Process
were	O
identified	O
by	O
General	B-Method
Health	I-Method
Questionnaire	I-Method
caseness	I-Method
,	O
a	B-Method
Center	I-Method
for	I-Method
Epidemiologic	I-Method
Studies	I-Method
Depression	I-Method
Scale	I-Method
score	B-Data
≥16	I-Data
,	O
and	O
use	O
of	O
antidepressant	B-Material
medication	I-Material
.	O
	
RESULTS	O
:	O
	
Diagnosed	B-Process
vascular	I-Process
disease	I-Process
(	O
that	O
is	O
,	O
coronary	B-Process
heart	I-Process
disease	I-Process
or	I-Process
stroke	I-Process
)	O
was	O
associated	O
with	O
an	B-Data
increased	I-Data
risk	I-Data
for	O
depressive	B-Process
symptoms	I-Process
,	O
age-	B-Data
and	I-Data
sex	I-Data
-	I-Data
adjusted	I-Data
odds	I-Data
ratios	I-Data
from	I-Data
1.5	I-Data
(	I-Data
95	I-Data
%	I-Data
confidence	I-Data
interval	I-Data
1.0	I-Data
-	I-Data
2.2	I-Data
)	I-Data
to	I-Data
2.0	I-Data
(	I-Data
1.4	I-Data
-	I-Data
3.0	I-Data
)	I-Data
,	O
depending	O
on	O
the	B-Data
indicator	I-Data
of	O
depressive	B-Data
symptoms	I-Data
.	O
	
Among	O
participants	B-Material
without	O
manifest	B-Process
vascular	I-Process
disease	I-Process
,	O
the	B-Data
Stroke	I-Data
Risk	I-Data
Score	I-Data
was	O
associated	O
with	O
Center	B-Method
for	I-Method
Epidemiologic	I-Method
Studies	I-Method
Depression	I-Method
Scale	I-Method
depressive	B-Data
symptoms	I-Data
before	I-Data
age	I-Data
65	I-Data
(	O
age-	B-Data
and	I-Data
sex	I-Data
-	I-Data
adjusted	I-Data
odds	I-Data
ratio	I-Data
per	I-Data
10	I-Data
%	I-Data
absolute	I-Data
change	I-Data
in	I-Data
the	I-Data
score	I-Data
=	I-Data
3.1	I-Data
[	I-Data
1.5	I-Data
-	I-Data
6.5	I-Data
]	I-Data
)	O
,	O
but	O
none	O
of	O
the	B-Data
risk	I-Data
scores	I-Data
predicted	O
new	B-Data
-	I-Data
onset	I-Data
depressive	I-Data
symptoms	I-Data
in	O
those	B-Material
	
aged	I-Material
≥65	I-Material
(	O
odds	B-Data
ratios	I-Data
from	I-Data
.8	I-Data
to	I-Data
1.2	I-Data
)	O
.	O
	
CONCLUSIONS	O
	
:	O
These	O
data	O
suggest	O
that	O
public	B-Process
health	I-Process
measures	I-Process
to	O
improve	B-Process
vascular	B-Data
risk	I-Data
status	I-Data
will	O
influence	O
the	O
incidence	O
of	O
later	B-Data
-	I-Data
life	I-Data
depressive	I-Data
symptoms	I-Data
via	O
reduced	B-Data
rates	I-Data
of	O
manifest	B-Process
vascular	I-Process
disease	I-Process
.	O
	
